Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine by unknown
RESEARCH Open Access
Development of a therapy against
metastatic bladder cancer using an
interleukin-2 surface-modified MB49
bladder cancer stem cells vaccine
Yong-tong Zhu1,2†, Shi-yu Pang1†, Cheng-yong Lei1, Yang Luo1, Qing-jun Chu2 and Wan-long Tan1*
Abstract
Introduction: In previous study the streptavidin interleukin-2 (SA-IL-2)-modified MB49 vaccine was effective against
bladder cancer in a mouse model. However, a small portion of tumors regrew because the vaccine could not
eliminate MB49 bladder cancer stem cells (MCSCs). Accordingly, we developed a SA-IL-2-modified MCSCs vaccine
and evaluated its antitumor effects.
Methods: MCSCs were isolated and identified in cancer stem cells (CSCs) characters, with high expression of CSCs
markers, higher resistance to chemotherapy, greater migration in vitro, and stronger tumorigenicity in vivo. The
SA-IL-2 MCSCs vaccine was prepared and its bioactivity was evaluated. The protective, therapeutic, specific and
memory immune response in animal experiments were designed to identify whether the vaccine elicited antitumor
immunity and acted against metastatic bladder cancer.
Results: MCSCs had higher level of CD133 and CD44, less susceptibility to chemotherapy, more pronounced
migration and greater tumorigenic ability. The successfully prepared SA-IL-2 MCSCs vaccine inhibited the tumor
volume and prolonged mice survival in animal experiments. The expression of IgG, the population of dendritic cells,
CD8+ and CD4+ T cells were highest in the experimental group than in the four control groups.
Conclusions: The SA-IL-2 MCSCs vaccine induced an antitumor immune response and was used to eliminate
MCSCs to prevent tumor regrowth.
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Introduction
Bladder cancer is the second most common urologic
cancer after prostate cancer in the United States and the
world [1]. For muscle invasive cancers, the standard
treatment is radical cystectomy with pelvic lymphade-
nectomy. Nevertheless, more than 50 % of patients who
undergo treatment will develop local or metastatic re-
currence [2]. The human interleukin-2 (IL-2) surface
modified MB49 bladder cancer cells vaccine induced
specific antitumor immunity and was effective against
metastatic bladder cancer in our previous study [3].
However, a small portion of the mouse bladder tumors
underwent regression and regrew after a period of time
because the cancer stem cells (CSCs) were not elimi-
nated. Recurrence of solid tumors may be due to the in-
ability of traditional chemotherapy and radiotherapy to
eliminate CSCs [4]. The vaccine used in our previous
study was not the CSCs vaccine and thus could not in-
duce specific immunity directed against CSCs. In this
study, MB49 bladder cancer stem cells (MCSCs) were
successfully isolated by a modified approach based on a
combination of limited dilution methods and serum-free
culture medium (SFM) methods used in previous studies
[5]. Thus, we developed a technology on the foundation
of previous protein-anchor technology, produced a
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streptavidin mouse interleukin-2 (SA-IL-2)-modified
MCSCs vaccine, and evaluated the antitumor effects of
this vaccine in a MCSCs metastatic mouse model.
Methods
Establishment of MCSCs
MB49, a mouse bladder cancer cell line, was a gift from
Dr. I. C. Summerhayes from the Lahey Clinic in Burlington,
Massachusetts, USA. [3]. MCSCs were isolated from
MB49 cells using a combination of limited dilution and
SFM methods in our previous study [5].
Identification of CSCs characters in MCSCs
MCSCs generated the next passages in 15 days. First, it
is necessary to identify MCSCs in CSCs characters with
high expression of CSCs markers, higher resistance to
chemotherapy, greater migration in vitro, and stronger
tumorigenicity in vivo.
Flow cytometry
MCSCs and MB49 cells were harvested separately, disso-
ciated and labeled with fluorescein isothiocyanate (FITC)
mouse antiCD44 (Miltenyi Biotec, Bergisch Gladbach,
Germany) and phycoerythrin (PE) mouse anti-prominin-
1 (Miltenyi Biotec). FITC rat IgG2b κ isotype control
(eBioscience, San Diego, CA, USA) and PE rat IgG1 κ
isotype control (eBioscience) were used as the negative
control. The ratio of CD133+CD44+ cells was evaluated
using a BD FACSAria cell sorter (Becton-Dickinson, San
Jose, CA, USA).
Western blotting
The protein extracts were separated by electrophoresis
and transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, MA, USA). Membranes were blocked
and incubated using the primary antibody anti-CD133
(Abcam, Cambridge, MA, USA), anti-CD44 (Abcam) and
anti-β-actin antibody (Abcam). Then membranes were in-
cubated with anti-mouse secondary antibodies (Abcam).
Finally, protein bands were detected using Fluor Chem
FC2 (Alpha Innotech, San Leandro, CA, USA) and their
intensity was analyzed using the Image Lab software.
Quantitative polymerase chain reaction
Total RNA was isolated using Arcturus PicoPure RNA
isolation kit (Arcturus, Life Technologies, Union City,
CA, USA). The RNA quality was verified using Bioanaly-
zer RNA Pico Chip (Agilent Technologies, Santa Clara,
CA, USA). cDNAs were synthesized by reverse tran-
scription using the Superscript III reverse transcriptase
(Invitrogen, Union City, CA, USA). cDNAs were ampli-
fied using SYBR green PCR master mix (Bio-Rad,
Hercules, CA, USA) on a 7500 real time PCR system
(AB Applied Biosystems, Singapore). The sequences of
the primers used are listed in Table 1. GAPDH was used
as a negative control.
Chemotherapy-resistance ability
The cells were seeded onto a 96-well plate at a density
of 1 × 104 per well. The chemotherapeutic agents pacli-
taxel (Sigma, Saint Louis, MO, USA) and cisplatin
(Sigma) were added at different concentrations. After
four days, CCK-8 was added and the absorbance value
was recorded. Cell viability was calculated as the per-
centage points of the absorbance values in treated wells
relative to untreated control wells.
Migratory ability in vitro
Cells were seeded, in pure RPMI1640 (1 × 104 cells/
0.25 ml/well), onto the upper well, and a 6.5-mm pore-
size polycarbonate membrane chamber was inserted into
the transwell apparatus (Costar, Cambridge, MA, USA).
RPMI1640 containing 10 % fetal bovine serum (FBS)
was added into the lower well. Cells were incubated and
migrated to the bottom surface after 24 hours, fixed,
stained, rinsed and examined by inverted microscopy.
Tumorigenic ability in vivo
All animal experiments performed were approved by the
Ethics Committee of Southern Medical University under
Contract 1116904. Cells were injected subcutaneously
into four-week-old nude mice (Center of Experimental
Animals, Southern Medical University, Guangzhou,
China) at 1 × 106 MB49 cells/mouse or 1 × 104 MCSCs/
mouse. The volume of the tumor xenograft was ob-
served every week, removed at week 8 and measured.
Preparation of SA-IL-2 MCSCs vaccine
Vaccine preparation
MCSCs were fixed in 30 % ethanol at room temperature
for 30 minutes. Then ethanol-fixed MCSCs were in-
cubated with EZ-Link Sulfo-NHS-LC-Biotin (Pierce
Biotechnology, Rockford, IL, USA). The biotinylated
cells were incubated with the SA-IL-2 fusion protein
produced in our lab [3]. The final purified product was
the SA-IL-2 MCSCs vaccine.
Table 1 Primers of selected genes
Gene name Primers (forward/reverse) Base pairs
of product
CD133 F: 5′-CGGGATCCGAAAAACTGATCTGT-3′ 615 bp
R: 5′-CCGCTCGAGTTACCTAGTTACTCTCTCC-3′
CD44 F: 5′-CCCTGCTACCAGAGACCAAGAC-3′ 401 bp
R; 5′-GCAGGTTCCTTGTCTCATCAGC-3′
GAPDH F: 5′-CCATGGAGAAGGCTGGGG-3′ 198 bp
R: 5′-CAAAGTTGTCATCCATGACC-3′
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Evaluation of SA-IL-2 on the surface of MCSCs
Vaccine was labeled with FITC anti-IL-2 monoclonal
antibody (BD Biosciences Pharmingen, San Diego, CA,
USA) and evaluated using a BD FACSAria cell sorter. Bi-
otinylated cells were used as the control group.
Bioactive assay of SA-IL-2 immobilized on the surface of
MCSCs
After the vaccine was lysed, membrane fractions were
harvested and suspended in complete medium. The SA-
IL-2 bioactivity was evaluated through proliferation in
bone marrow cells (BMCs), while the SA-green fluores-
cent protein (GFP) was used as the control. Membrane
fractions and BMCs were incubated in 96-well plates,
CCK-8 was added and the absorbance value was recorded
as described previously.
Level of IL-2 on the vaccine
The level of IL-2 antibody on the vaccine was measured by
Western blotting (WB) as described previously. The primary
antibodies were anti- IL-2 (Abcam) and anti-beta II tubulin
(Abcam), while SA-GFP was used for the control group.
Animal experiments
Animal experiments were performed to ascertain whether
the SA-IL-2 MCSCs vaccine elicited antitumor immunity
and acted against metastatic bladder cancer. After estab-
lishing the mouse model, the experiments to investigate
the protective, therapeutic, specific and memory immune
responses were separately designed and conducted. Dur-
ing the therapeutic immune response experiment, some
serum markers were specifically examined to study the
mechanism of the SA-IL-2 MCSCs vaccine.
Lung metastasis and subcutaneous mouse model of MCSCs
C57BL/6 female mice were injected intravenously in the
tail vein with 2 × 104 MCSCs to establish a lung metasta-
sis model. Mice were injected with 1 × 105 MCSCs into
the hind leg to establish a subcutaneous model.
Protective immune response experiment
All mice in the subcutaneous and pulmonary models
were divided into five groups and every group consisted
of 15 mice. The experimental group was given the SA-
IL-2 MCSCs vaccine. The other groups received either
ethanol-fixed MCSCs, SA-IL-2 MB49 cells vaccine, SA-
IL-2, or phosphate-buffered saline (PBS).
Mice received the vaccines or other reagents in ad-
vance, and then were planted with MCSCs to observe
the protective role of the vaccines. First, mice were inoc-
ulated with the SA-IL-2 MCSCs vaccine or other re-
agents subcutaneously on days 0, 4 and 8. Then mice
received MCSCs on day 12 to establish the lung metas-
tasis and the subcutaneous models as previously
described. The survival time was recorded and the vol-
ume of subcutaneous tumors was measured.
Therapeutic immune response experiment
Mice were planted with MCSCs in advance, and then re-
ceived the vaccine or other reagents to investigate the
therapeutic role of vaccines. Mice were divided into five
groups as mentioned above. First, the lung metastasis and
subcutaneous model mice were established. Then, mice
were injected with the SA-IL-2 MCSCs vaccines or other
reagents on days 0, 4, 8 and 12. The survival rate and the
volume of the subcutaneous tumors were measured.
Specific immune response experiment
Mice were planted with MCSCs and prostate cancer cells
to investigate the specific role of the vaccines. On day 60
of the immunotherapy experiment, surviving or tumor-
free mice were injected subcutaneously with RM-1 cells in
the left hind leg and MCSCs in the right hind leg. The vol-
ume of the subcutaneous tumors was measured.
Memory immune response experiment
Mice were planted with MCSCs again to observe the
role of vaccines on memory immunity. On day 60 of the
protective and immunotherapy experiment, surviving
mice in the lung metastasis experiment or tumor-free
mice in the subcutaneous experiment were injected with
1 × 105 MCSCs intravenously again. Blank mice were used
as the control group, and survival time was recorded.
Tumor specific lymphocyte cytotoxicity assay
Splenocytes were isolated on day 19 and stimulated with
the inactivated MCSCs plus hIL-2 (20 U/mL, R&D systems,
Minneapolis, MN, USA) for five days. MCSCs and spleno-
cytes were seeded onto 96-well plates, incubated and subse-
quently used as target and effector cells, separately. Lactate
dehydrogenase activity was measured using the cytotox 96
non-radioactive cytotoxicity assay (Promega, Madison, WI,
USA). The percentage of tumor specific cytotoxic T lym-
phocytes (CTL) was calculated as previously described [3].
ELISA for serum IgG antibodies
Blood was collected on day 19, congealed and the super-
natant was harvested. The concentrations of IgG were
measured using ELISA kits (Abcam) according to the
manufacturer’s protocol. Optical density (OD) value was
measured at 450 nm using a microplate reader.
Flow cytometry of dendritic cells
Splenocytes were isolated on day 19 and red blood cells
were lysed. Splenocytes were labeled with PE anti-
mCD11c (Biolegend, San Diego, CA. USA) and FITC
anti-mCD80 (Biolegend). The ratio of CD11c+CD80+ cells
was measured using a BD FACSAria cell sorter.
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Flow cytometry of T cell subsets
Blood was collected on day 19 and stained with FITC
anti-mCD8 (eBioscience) and PE anti-mCD4 (eBioscience).
Then red blood cells were lysed and the ratio of CD8+ and
CD4+ cells was measured using a BD FACSAria cell sorter.
Statistical analysis
All analyses were performed by the SPSS19.0 software,
setting significance at P < 0.05. Numeric data were
expressed as the mean ± standard deviation and analyzed
by Student’s t-test (between two groups) or one-way ana-
lysis of variance (ANOVA) (>2 groups). Survival rates were
analyzed by the Kaplan-Meier method, and differences in
survival between groups were analyzed by the log-rank test.
Results
Identification of MCSCs in CSCs characters
Flow cytometry (FCM) analysis revealed that the fraction
of CD44+CD133+ cells was 25.97±1.31 % in MCSCs and
12.70±0.66 % in MB49 cells (Fig. 1a). The WB analysis
indicated that the CD133 and CD44 proteins were abun-
dantly expressed in MCSCs, but much less in MB49 cells
(Fig. 1b). The qPCR analysis showed that the relative
levels of CD133 and CD44 mRNAs in MCSCs were 2.7
and 4.7 times higher, respectively, than those observed
in MB49 cells (Fig. 1c).
Compared to MB49 cells, MCSCs displayed higher cell
viabilities after being exposed to different concentrations
of paclitaxel and cisplatin, which suggested that MCSCs
had lower susceptibility to traditional anticancer agents
(Fig. 1d).The results of the transwell migration assay in-
dicated that more MCSCs invaded the bottom chamber
when compared to MB49 cells under the same incuba-
tion conditions, which suggested that MCSCs had higher
invasion ability than MB49 cells (Fig. 1e). Regarding
xenograft formation, MCSCs produced tumors with lar-
ger volumes than MB49 cells did with the same number
of injections (Fig. 1f ).
Fig. 1 Identification of MCSCs in CSCs characters. a FCM analysis showed that the fraction of CD44+CD133+ cells in the MCSCs population was
larger than in MB49 cells. b WB analysis showed that CD133 and CD44 were abundantly expressed in MCSCs but poorly expressed in MB49 cells.
β-actin was used as a protein loading control. c qPCR analysis revealed that the relative levels of CD133 and CD44 mRNA in MCSCs were higher
in MB49 cells. d MCSCs exhibited higher cell viabilities after being exposed to different concentrations of paclitaxel and cisplatin. e In the transwell
migration assay, the number of invasive MCSCs was higher than that of MB49 cells. f In xenograft formation experiments, MCSCs produced larger
tumor volumes than MB49 cells did. *P < 0.05 (vs MB49 cells). MCSCs MB49 bladder cancer stem cells, CSCs cancer stem cells, FCM flow cytometry,
WB Western blot, qPCR quantitative polymerase chain reaction
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Preparation of SA-IL-2 MCSCs vaccine
According to the results of the FCM analysis, the por-
tion of MCSCs anchored with SA-IL-2 was 88.7 ± 1.1 %
(Fig. 2a). Meanwhile, the WB analysis revealed that the
IL-2 antibody was abundantly expressed on the vaccine
(Fig. 2b). In addition, the CCK-8 assay results indicated
that the proliferation of BMCs was stimulated by mem-
brane bound IL-2 in a dosage dependent manner
(Fig. 2c). These results showed that SA-IL-2 could be ef-
ficiently anchored on the outside of MCSCs and retained
its biological activity well.
Animal experiment
MCSCs vaccine induces a protective immune response
In the subcutaneous model mice, the mean tumor vol-
ume in the experimental group was 156.3 mm3, and it
exhibited a trend towards significantly smaller tumor
volumes compared with the four control groups. Specif-
ically, the mean tumor volumes in the groups receiving
the SA-IL-2 MB49 cells vaccine, ethanol-fixed MCSCs,
SA-IL-2, and PBS were 416.3, 659.3, 723.8, and 965.9 mm3,
respectively (Fig. 3a).
In the pulmonary model mice, the survival rate in the
experimental group was 50.8 days, and displayed a trend
towards a significantly longer survival rate compared
with the four control groups, whose survival rates were
44.3, 33.5, 33.9, and 31.7 days, respectively (Fig. 3b).
Therapeutic immune response experiment
In the subcutaneous model mice, the mean tumor vol-
ume in the experimental group was 163.1 mm3, and ex-
hibited a trend towards significantly smaller tumor
volumes compared with the four control groups. Specif-
ically, the mean tumor volumes in the groups receiving
the SA-IL-2 MB49 cells vaccine, ethanol-fixed MCSCs,
SA-IL-2, and PBS were 425.5, 657.9, 714.9, and 946.0 mm3,
respectively (Fig. 3c).
In the pulmonary model mice, the survival rate in the
experimental group was 50.2 days, and exhibited a trend
towards a significantly longer survival rate compared
with the four control groups whose survival rates were
44.2, 32.2, 33.3, and 31.0 days, for the SA-IL-2 MB49
cells vaccine, ethanol-fixed MCSCs, SA-IL-2, and PBS
groups, respectively (Fig. 3d).
Specific immune response with MCSCs vaccines
The mean tumor volume on the MCSCs injected side
(120.4 mm3) was significantly smaller than that on the
RM-1 cells injected side (1342.0 mm3), as shown in
Fig. 3e. Such a result indicated that the SA-IL-2 vaccine
could establish a firm tumor specific T cell immunity.
Memory immune response with MCSCs vaccines
After administering a second challenge of MCSCs, the
survival rate in the experimental group (56.8 days) was
significantly longer than that of the control group
(29.8 days), as shown in Fig. 3f. Such a result demon-
strated that the SA-IL-2 vaccine could produce long-
term memory immunity.
Tumor-specific lymphocyte cytotoxicity assays
The portion of CTL was found to be significantly higher
in the experimental group than in the four control
groups (Figs. 4a and 5a). Such findings showed that the
SA-IL-2 vaccine could establish a firmer tumor specific
T cell immunity.
Fig. 2 Analysis of the SA-IL-2 MCSCs vaccine. a Typical FCM analysis image of MCSCs anchored with SA-IL-2. b WB analysis showed that the IL-2
antibody was abundantly expressed on the vaccine. c CCK-8 assay showed that the proliferation of BMCs was stimulated by membrane bound
IL-2 in a dosage dependent manner. SA-GFP was used as a control group. *P < 0.05 (vs control group) SA-IL-2 streptavidin mouse interleukin-2,
MCSCs MB49 bladder cancer stem cells, WB Western blot, BMCs, bone marrow cells, GFP green fluorescent protein
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Detection of serum IgG antibodies
The expression of serum IgG antibodies in the experi-
mental group was significantly higher than in the four
control groups (Figs. 4b and 5b). Such an increased level
of IgG could enhance the antitumor immunity effect in
mice.
Number of DCs
According to the FCM analysis results, the portion of
DCs (CD11c+CD80+) was significantly larger in the
experimental group than in the four control groups
(Figs. 4c and 5c). This result demonstrated that the SA-
IL-2 vaccine could enhance the mature DCs population.
Number of T cell subsets
According to the findings of the FCM analysis, the por-
tion of CD8+and CD4+ T cells in the experimental group
was significantly larger than in the four control groups
(Figs. 4d and 5d). Such an increased level of CD8+ and
CD4+T lymphocytes could heighten the antitumor im-
munity effect in mice.
Discussion
In this study an effective vaccine immunotherapy target-
ing CSCs was developed. To our knowledge, there has
been little reported about therapy targeting the CSCs
population in bladder cancer [6].
Fig. 3 Animal experiment with the SA-IL-2 MCSCs vaccine. a In the protective experiment, experimental group mice exhibited a trend towards
the smallest tumor volume. b In the protective experiment, mice in the experimental group had a longest survival. c In the therapeutic
experiment, experimental group mice showed a trend towards the smallest tumor volume. d In the therapeutic experiment, experimental group
mice had the longest survival. e In the specific experiment, experimental group mice showed a trend towards smaller tumor volume. f In the
memory experiment, experimental mice group had a longer survival, SA-IL-2 streptavidin mouse interleukin-2, MCSCs MB49 bladder cancer stem
cells, PBS phosphate-buffered saline
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Similar to other methods [7] used to isolate CSCs,
MCSCs isolated from MB49 cells in our previous study
[5] were not 100 % pure of CSCs. The CD44 and CD133
markers were used to identify CSCs in tumor tissues [8,
9]. Additionally, our study found elevated expression
levels of CD133+ and CD44+ in MCSCs (Fig. 1a-c). Tar-
geting CD44+ and CD133+ cancer cells or pathways in-
volving a CD133+CD44+ cell subpopulation might be a
Fig. 4 Antitumor potency of the SA-IL-2 MCSCs vaccine in the pulmonary model mice. a In the cytotoxicity assay, the portion of CTL in the experimental
group was significantly higher than in the four control groups. b In ELISA assay, the expression of serum IgG antibodies in the experimental group was
significantly higher than in the four control groups. c FCM analysis showed that the portion of DCs (CD11c+CD80+) in the experimental group was
significantly larger than in the four control groups. d FCM analysis showed that the portion of CD8+and CD4+ T cells in the experimental group was
significantly larger than in the four control groups. *P < 0.05 (vs experimental group). SA-IL-2 streptavidin mouse interleukin-2, MCSCs MB49 bladder
cancer stem cells, CTL cytotoxic T lymphocytes, ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin G, FCM flow cytometry, DCs dendritic
cells, PBS phosphate-buffered saline
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strategy for colorectal cancer therapy [10]. Thus CD133
+CD44+ cells may be the enriched CSC subpopulation in
MB49 bladder cancer cell populations. MCSCs used in
experiments were enriched for CD133+ and CD44+
markers, but not seen to be 100 % dual positive cells by
FCM analysis (Fig. 1a). In addition, the expression of
both markers was found elevated in MCSCs not only at
the mRNA expression (qPCR) level (Fig. 1c), but also at
Fig. 5 Antitumor potency of the SA-IL-2 MCSCs vaccine in the subcutaneous model mice. a In the cytotoxicity assay, the portion of CTL in the
experimental group was significantly higher than in the four control groups. b In ELISA assay, the expression of serum IgG antibodies in the
experimental group was significantly higher than in the four control groups. c FCM analysis showed that the portion of DCs (CD11c+CD80+) in
the experimental group was significantly larger than in the four control groups. d FCM analysis showed that the portion of CD8+and CD4+ T cells
in the experimental group was significantly larger than in the four control groups. *P < 0.05 (vs experimental group). SA-IL-2 streptavidin mouse
interleukin-2, MCSCs MB49 bladder cancer stem cells, CTL cytotoxic T lymphocytes, ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin G,
FCM flow cytometry, DCs dendritic cells, PBS phosphate-buffered saline
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the protein expression (WB) level (Fig. 1b). There were
other markers that have been used to identify CSCs from
tumors, such as ABC transporters, aldehyde dehydro-
genase, and so on. Detecting the status of these markers
will help us to understand MCSCs in further research.
We functionally characterized the MCSCs populations
by different techniques [11, 12]. Specifically, MCSCs had
a greater ability to penetrate wells (Fig. 1e). Moreover,
although chemotherapy killed most tumor cancer cells,
it could not kill CSCs. Additionally, MCSCs exhibited a
lower sensitivity to paclitaxel and cisplatin (Fig. 1d),
which might be consistent with the theory of resistance
to chemotherapy [13, 14]. Tumorigenicity in nude mice
was the standard method used to evaluate the tumorigenic
ability of CSCs [15]. MCSCs had a greater ability to form
subcutaneous tumors in nude mice (Fig. 1f). Taking all
the above results together, MCSCs showed specific CSC
properties.
Although in previous study the SA-IL-2 MB49 cells
vaccine induced antitumor immunity to MB49 cells and
killed the tumor, it did not induce specific immunity to
MCSCs. Accordingly, a small portion of the mice devel-
oped tumors again within a certain period of time be-
cause MCSCs were not eliminated. In order to eliminate
MCSCs, the SA-IL-2 MCSCs vaccine was produced on
the basis of previous vaccine [3], and the surface modifi-
cation of the MCSCs vaccine was able to induce antitu-
mor immunity to MCSCs.
Although the SA-IL-2 MB49 vaccine had effect on ex-
perimental group (MCSCs) than other control groups
(ethanol-fixed MCSCs, SA-IL-2 and PBS). Compared to
the original vaccine, the SA-IL-2 MCSCs vaccine effi-
ciently inhibited the tumor growth and prolonged the sur-
vival of mice (Fig. 3a-d). Moreover, effector cells inhibited
MCSCs growth in vitro in cytotoxicity assay, and mice
were resistant to a second administration of the MCSCs
after being successfully treated by the vaccine (Figs. 4a
and 5a). As IgG accounts for more than 80 % of total Ig,
the serum level of IgG reflects the level of total Ig. Our
study detected an elevated higher serum IgG level in the
experimental group than in the four control groups
(Figs. 4b and 5b). Such a result indicated that the im-
munotherapy with the SA-IL-2 MCSCs vaccine could in-
duce antitumor specific immunity against MCSCs.
In order to eliminate MCSCs, the current study using
the SA-IL-2 MCSCs vaccine performed similar studies
previously conducted with SA-IL-2 MB49 vaccine. Con-
sidering the role of the original vaccine, a combination
using MCSCs vaccine and MB49 vaccine maybe a better
treatment, as one targets the bladder cancer cells and
the other targets the bladder CSCs for successful treat-
ment of bladder cancer.
IL-2 could promote the transition of DCs from imma-
ture to mature forms, and plays an important role in the
growth of DCs during immune response [16]. However,
the impact of anticancer immunity depends on the func-
tion of T lymphocytes. DCs are the most effective antigen
presenting cells and regulate T lymphocyte-mediated im-
munity [17]. MCSCs vaccine elicited an immune response
mediated by T lymphocytes, such as the reaction of ef-
fector T cells targeting CSCs and the increase in CD8+
and CD4+ T cells [18]. Thus, CD8+ and CD4+ T lympho-
cyte cells are the primary effector cells in antitumor im-
munity. The vaccine containing CSCs antigens could lead
to strong antitumor T cell immunity [19]. Therefore, IL-2,
DCs and T lymphocytes are closely connected in the anti-
tumor response. MCSCs can be identified and eliminated
by CD8+ and CD4+ T lymphocytes, and the immunosup-
pressive effects of MCSCs can be overcome in mice tumor
models.
There are some limitations that needed to be taken
into account. During the animal experiments, it would
be better to test the MCSCs vaccine on MB49 cells alone
because MB49 cells also contained CD133+ and CD44+
dual positive cells. Considering that MCSCs had a higher
level of CD133 and CD44, less susceptibility to chemo-
therapy, more pronounced migration and greater tumori-
genic ability than MB49 cells, it was assumed that MCSCs
vaccine alone would be effective to eliminate the entire
population of MCSCs and MB49 cells. And the experi-
ments that the mice injected with MB49 cells treated with
the MCSCs vaccine are going to be recommended in the
future. Furthermore, MCSCs were not 100 % pure of
CSCs, so MCSCs vaccine did not induce 100 % tumor re-
gression. MCSCs were able to give rise to MCSCs and
MB49 cells, and generally CSCs were considered to be a
rare population and eventually non-CSCs over populate
the tumor. Although it was assumed that MCSCs vaccine
would be effective to eliminate CSCs and non-CSCs, a
better treatment using MCSCs vaccine and MB49 vaccine
simultaneously is also recommended in the future.
Conclusions
SA-IL-2 MCSCs vaccine was successfully produced and
used to eliminate MCSCs to prevent tumor recurrence.
However, the exact mechanism of the vaccine is still
poorly understood. A better understanding of the func-
tional aspects of the MCSCs vaccine could ultimately lead
to clinical trials and eventually to its use to fight cancer in
humans. A vaccine containing general cancer antigens or
patient specific antigens may be the direction to follow for
the development of a clinical vaccine in the future.
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